DE-INCYTE
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31); and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14).
“We are pleased to have virtual platforms such as ASCO20 and EHA25 to continue sharing important data with the scientific community in a timely manner,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “These data demonstrate the strength of our broad oncology portfolio and our partnerships; and reinforce our commitment to finding solutions that can help meet patients’ needs.”
Key abstracts accepted by ASCO and EHA include:
ASCO Abstracts
Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, May 29, 2020, 8:00 AM ET.
Oral Presentations
Capmatinib in Patients with High-Level MET -Amplified Advanced Non-Small Cell Lung Cancer (NSCLC): Results from the Phase 2 GEOMETRY mono-1 Study (Abstract #9509, Session: MET Mutations: The Meat of the Matter)1
Interim Analysis (IA) of OPTIC: A Dose-Ranging Study of Three Ponatinib (PON) Starting Doses (Abstract #7502, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2
E-Poster Presentations
An Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase 2 PACE Trial (NCT01207440) in Patients (pts) with Ph+ Leukemia (Abstract #7550, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2
Re-MIND Study: A Propensity Score-Based 1:1 Matched Comparison of Tafasitamab + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #8020, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia)3
Safety and Efficacy of Pemigatinib Plus Pembrolizumab Combination Therapy in Patients (pts) with Advanced Malignancies: Results from FIGHT-101, an Open-Label Phase 1/2 study (Abstract #3606, Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology)
Capmatinib in Patients with METex14 -Mutated or High-Level MET -Amplified Advanced Non-Small-Cell Lung Cancer (NSCLC): Results from Cohort 6 of the Phase 2 GEOMETRY mono-1 study (Abstract #9520, Session: Lung Cancer—Non-Small Cell Metastatic)1
Pan-Cancer Analysis of FGFR1-3 Genomic Alterations to Reveal a Complex Molecular Landscape (Abstract #3620, Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology)
EHA Abstracts
Oral abstract presentations and e-posters accepted for presentation at EHA will be available on the on-demand Virtual Congress platform beginning Friday, June 12, 2020, at 8:30 AM CEST.
Oral Presentations
Addition of Parsaclisib, a PI3Kδ inhibitor, in Patients with Suboptimal Response to Ruxolitinib (Rux): A Phase 2 Study in Patients (Pts) with Myelofibrosis (MF) (Abstract #S216, Session: Novel Therapies and Pitfalls in MPN)
Ruxolitinib Versus Best Available Therapy in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: Overall Response Rate by Baseline Characteristics in the Randomized Phase 3 REACH2 Trial (Abstract #S255, Session: Stem Cell Transplantation – Clinical: Graft-Versus-Host Disease)1
GRAVITAS-301: A Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for Initial Treatment of Patients with Acute Graft-Versus-Host Disease (Abstract #S256, Session: Stem Cell Transplantation – Clinical: Graft-Versus-Host Disease)
Interim Analysis from the OPTIC Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib (Abstract #S172, Session: Chronic Myeloid Leukemia (CML) Clinical)2
Re-MIND Study: Comparison of Tafasitamab + Lenalidomide (L-Mind) vs Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Abstract #S238, Aggressive Lymphomas: Observational Studies)3
E-Poster Presentations
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Ruxolitinib Exposed vs Unexposed (Abstract #EP1124, Session: Myeloproliferative Neoplasms – Clinical)
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Pre- vs Post-Ruxolitinib Approval (Abstract # EP1120, Session: Myeloproliferative Neoplasms – Clinical)
Machine-Learning to Predict Hydroxyurea (HU) Failure and Incidence of Thromboembolic Events (TEs) with HU vs Ruxolitinib Switch Therapy in Polycythemia Vera Patients (Abstract #EP1117, Session: Myeloproliferative Neoplasms – Clinical)1
Patient-Reported Physical, Emotional and Economic Impact of Myeloproliferative Neoplasms in an Expansion of the MPN Landmark Survey (Abstract #EP1112, Session: Myeloproliferative Neoplasms – Clinical)1
Ruxolitinib in PV Patients Resistant and/or Intolerant to Hydroxyurea: Interim Analysis of a European Multi-Centric Observational Study (Abstract #EP1115, Session: Myeloproliferative Neoplasms – Clinical)1
Treatment and Disease Management Practices in Patients with MPNs in 6 Countries: An Expansion of the MPN Landmark Survey (Abstract #EP1123, Session: Myeloproliferative Neoplasms – Clinical)1
Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Phase 2 PACE Trial of Ponatinib in Philadelphia Chromosome Positive (Ph+) Leukemia (Abstract #EP759, Session: Chronic Myeloid Leukemia (CML) Clinical)2
The Real–Life Study Evaluating the Efficacy and Safety of Ponatinib “Topase” Reveals Induction of Deep Molecular Responses in a Cohort of 75 TKI-Resistant or Intolerant patients with CML (Abstract #EP765, Session: Chronic Myeloid Leukemia (CML) Clinical)
Combination of Tafasitamab (MOR208) and Lenalidomide Enhances Tumor Cell Death of B-cell Lymphoma in Vitro (Abstract #EP1343, Session: Lymphoma Biology & Translational Research)3
Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (Mor208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Abstract #EP1201, Session: Aggressive Non-Hodgkin Lymphoma - Clinical)3
Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells After Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data (Abstract #EP671, Chronic Lymphocytic Leukemia and Related Disorders - Biology & Translational Research)3
For full session details and data presentation listings, please see the ASCO20 (https://meetinglibrary.asco.org ) and EHA25 (https://learningcenter.ehaweb.org/eha ) online programs.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com
and follow @Incyte
.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO and EHA meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended March 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Novartis-sponsored; 2 Takeda-sponsored; 3 MorphoSys-sponsored
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005695/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAYTUS Completes 100-Cabinet Liquid-Cooled Data Center in Europe in Four Months6.1.2026 09:02:00 CET | Press release
KAYTUS turnkey modular solution delivered with onsite professional services, improved high-density liquid cooling cluster performance by 20%, and deployment efficiency by 80%. KAYTUS announced that it has accelerated the deployment of large-scale liquid-cooled AI data centers through its integrated turnkey service. By combining deployment and commissioning, KAYTUS delivers a one-stop, end-to-end service, from installation to optimization and launch. Recently, KAYTUS completed the delivery of a 100-cabinet, high-density liquid-cooled AI data center in Europe in just four months, up to 80% faster than traditional deployment models. Through professional performance testing and tuning, overall system performance was improved by 20%, enabling a stable, high-efficiency business launch through on-site optimization and customization. This accelerated and resilient delivery addresses urgent AI infrastructure timelines and provides a scalable blueprint for deploying high-density liquid-cooled cl
Kashiv BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conference6.1.2026 09:00:00 CET | Press release
Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of Business Development, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 14, 2026, at 11:00 a.m. PST. 44th Annual J.P. Morgan Healthcare Conference – Kashiv BioSciences Company Presentation Date: Wednesday, January 14, 2026 Time: 11:00 - 11:25 a.m. PST Location: Golden Gate Conference Room – The Westin St. Francis Hotel, San Francisco, California About Kashiv BioSciences: Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together “Kashiv BioSciences”) operat
CES 2026: GIGABYTE is “AI Forward,” Showcasing AI Factory, Physical AI, and Agentic AI Solutions6.1.2026 01:00:00 CET | Press release
GIGABYTE Technology, a global leader known for its engineering excellence in high-performance computing and AI servers, continues to strengthen its position as one of Taiwan’s most AI-centric server innovators. At CES 2026, GIGABYTE is to present its complete computing ecosystem under the theme “AI Forward”—highlighting how its technologies form the computational backbone of next-generation AI infrastructure, supporting AI development across cloud, edge, and personal devices, and full-stack solutions enabling organizations to deploy AI with greater speed, scale, and efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251224890815/en/ CES 2026: GIGABYTE is “AI Forward,” Showcasing AI Factory, Physical AI, and Agentic AI Solutions Build Future-Ready AI Factory GIGABYTE introduces its one-stop AI data center solution with GIGAPOD, a modular “Building-Block Design” that integrates high-performance servers, high-speed netw
Cooler Master Launches the MasterFrame 360 Series With Panorama, Stage Mirror and Stage LCD Versions5.1.2026 18:41:00 CET | Press release
Designed for Powerful PC Builds and Personal Expression — A Showcase Without Limits Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the launch of the MasterFrame 360 Series. This new family of PC cases is designed for creators and enthusiasts who want a powerful PC build and a platform to express their personal style and be their “Showcase Without Limits.” With advanced cooling capacity and a 360-degree display stage, the series offers a blend of performance and presentation. Across the series, the MasterFrame 360 platform gives builders space for up to twelve 120 mm fans or a mix of 120, 140, and 200 mm options. Support for radiators up to 360 mm, plus clearance for flagship GPUs and PSUs, ensures great cooling no matter what you are doing. With compatibility for Mini-ITX, Micro-ATX, ATX, and BTF (back-connect) motherboards, every build remains clean, optimized, and future-ready. “Our community builds PCs that reflect who they are,” said M
Cooler Master Introduces COSMOS Alpha5.1.2026 18:38:00 CET | Press release
A PC Case for Unlimited Layout, Cooling, and Customized Builds Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced COSMOS Alpha, the next evolution of its iconic COSMOS series. The COSMOS Alpha reflects Cooler Master’s commitment to FreeForm 2.0 with its modular, open, and customizable technology. It gives boundary-pushing PC builders the freedom to shape the form and performance of their system. “COSMOS has always represented the height of craftsmanship and customization,” said Matteo Stracciari, General Manager of Cooler Master. “COSMOS Alpha carries that legacy forward in a flagship platform where every detail can be adjusted, optimized, or reimagined to match a builder’s vision.” A Signature Flagship Design COSMOS Alpha preserves the series’ premium modular design with distinctive curved aluminum frames and tempered glass side panels. Under-case ARGB lighting adds a refined visual accent that complements performance builds and showcase syst
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom